Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633.

Chemotherapy Uptake and Wait Times in Early-Stage Non-Small-Cell Lung Cancer

“…Interestingly, in 2007 compared with 2005, patients with stage ib disease were less likely to be referred to medical oncology, and those referred at qeii hsc were less likely to receive adjuvant chemotherapy after referral. The decline in stage ib referrals was expected given the recently demonstrated lack of survival benefit for adjuvant chemotherapy in stage ib disease with small tumour size 8,14,24,25 . A recent Canadian study from Alberta similarly observed a significant decline in adjuvant chemotherapy uptake for stage i b lung cancer in 2006 compared with 2005 or 2004 13 .…”

“…Subsequently, a number of studies in a variety of jurisdictions observed adjuvant chemotherapy uptake rates of only 20%-30% for patients with early-stage nsclc after curative-intent surgery [11][12][13] . More recently, longer follow up from calgb 9633 found that the survival benefit associated with adjuvant chemotherapy in stage ib disease was no longer statistically significant 14 . As well, a subset analysis of ncic jbr.10 revealed that the survival benefit in stage ib disease was limited to patients with larger tumours 15 .…”

Non–Small Cell Lung Cancer

“…186,187 In this trial, 344 patients (aged 34-81 years) were randomly assigned to either carboplatin/paclitaxel or observation within 4 to 8 weeks of resection, with a median follow-up of 54 months. Adjuvant chemotherapy was well tolerated with no chemotherapy-related toxic deaths.…”

Pin1 expression contributes to lung cancer prognosis and carcinogenesis

“…The adjuvant chemotherapy had a beneficial effect on the survival of patients with resected NSCLC. [18][19][20][21][22] Based on these reports, adjuvant chemotherapy was recommended as a standard therapy for resected NSCLC. So, the 5-year survival rate is higher than the average.…”